Navigation Links
Boveran Diagnostics, Inc. Announces Planned Acquisition of New York-Based Pathology Lab: Sophora Diagnostic Lab, Inc.
Date:9/8/2008

OXFORD, Miss., Sept. 8 /PRNewswire-FirstCall/ -- Boveran Diagnostics, Inc. (OTC Bulletin Board: BOVD) ("Boveran") today announced its has executed a Letter of Intent ("LOI") to acquire majority interest in Sophora Diagnostic Lab, Inc., a New York-based cancer pathology lab ("Sophora").

Pursuant to the LOI, Dr. Mikhail Kantius will join Boveran Diagnostics as the Company's Chief Pathologist and Director of Lab operations and Business Development for pathology lab services.

Sophora is Boveran's first planned acquisition and headquarters for its new cancer detection system designs and technologies. Additional acquisitions are planned and will be announced as part of the Boveran's lab network revenue and growth plan.

Boveran will soon publish guidance on its planned acquisitions, complete business plan information, revenue models, and details on its new development initiative for its next generation fully-automated computer imaging cancer detection platform.

About Boveran Diagnostics, Inc.

Boveran Diagnostics, Inc. develops cancer detection technologies and markets this technology to pathology laboratories and other cancer diagnostic laboratories. The Company believes that the application of automated cancer detection technologies will provide physicians and laboratories with the genomic information necessary to determine the presence or absence of cancer by reducing the uncertainty for the pathologist and consumer by decreasing false positive and false negatives resulting from current conventional cancer diagnostic techniques. The Company's website can be found at http://www.boveran.com.

SEC Filings and Forward-Looking Statements

Additional information regarding Boveran Diagnostics, Inc, is contained in a Report on Form 8-K and Form 10-Q, filed with the Securities and Exchange Commission on July 31, 2008 and August 14, 2008, respectively, by Z Yachts, Inc.

Certain statements made in this release are forward-looking statements. Forward-looking statements are based on the then-current expectations, beliefs, assumptions, estimates and forecasts about the business of Boveran Diagnostics, Inc. and the industries and markets in which Boveran Diagnostics, Inc. operates. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or implied by these forward-looking statements. Boveran Diagnostics, Inc. expressly disclaims any intent or obligation to update these forward-looking statements to conform the statement to actual results or changes in the Company's expectations, except as otherwise specifically stated.

Investor Relations:

Contact: Boveran Diagnostics, Inc., info@boveran.com, 1-954-495-9334


'/>"/>
SOURCE Boveran Diagnostics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. FASgen Diagnostics, LLC Announces Production and Investment Agreement With Tetracore, Inc.
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... ... advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give ... Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles ...
(Date:10/10/2017)... 2017 SomaGenics announced the receipt of a ... RealSeq®-SC (Single Cell), expected to be the first commercially ... microRNAs) from single cells using NGS methods. The NIH,s ... accelerate development of approaches to analyze the heterogeneity of ... techniques for measuring levels of mRNAs in individual cells ...
(Date:10/9/2017)... ... October 09, 2017 , ... The award-winning American Farmer television series will ... American Farmer airs Tuesdays at 8:30aET on RFD-TV. , With global population estimates ... of how to continue to feed a growing nation. At the same time, many ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... for microscopy and surface analysis, Nanoscience Instruments is now expanding into Analytical ... broad range of contract analysis services for advanced applications. Services will leverage ...
Breaking Biology Technology:
(Date:8/23/2017)... general public,s help is being enlisted in what,s thought to be the ... the human body –and are believed to affect health.  ... The Microbiome Immunity Project is the largest study to ... The project's goal is to help advance scientific knowledge of the role ... The ...
(Date:6/23/2017)... ITHACA, N.Y. , June 23, 2017  IBM ... in dairy research, today announced a new collaboration using ... the chances that the global milk supply is impacted ... project, Cornell University has become the newest academic institution ... Chain, a food safety initiative that includes IBM Research, ...
(Date:5/16/2017)... DALLAS , May 16, 2017   ... for health organizations, and MD EMR Systems ... certified development partner for GE, have established a ... Patient Portal product and the GE Centricity™ products, ... Centricity EMR. These new integrations ...
Breaking Biology News(10 mins):